Dr Farber is a pediatrician in Woodbridge, Virginia.
Can fewer daily doses of cephalexin treat MSSA?
June 3rd 2020A pharmacokinetic model suggests that although 4 daily doses of cephalexin are the standard of care for treating methicillin-susceptible Staphylococcus aureus (MSSA) infections, 2- or 3-dose daily regimens (BID or TID) could achieve similar results.
PPI exposure increases risk of fractures
June 1st 2020Children who take proton pump inhibitors (PPIs) are at increased risk of having fractures compared with those who have no PPI exposure, according to a retrospective review of information in the Pediatric Hospital Information System database. Further, likely fracture location differs between those who are exposed to PPIs and those who are not.
Paternal smoking raises risk of acute lymphoblastic leukemia
May 7th 2020Paternal smoking before conception or during pregnancy are both associated with increased risk of acute lymphoblastic leukemia in offspring, and the risk is significant when daily smoking consumption is higher than a certain threshold, according to a recent meta-analysis.
SGA treatment raises risk of metabolic disturbances
April 3rd 2020Second-generation antipsychotics (SGAs), used alone or with other psychotropic medications, are associated with metabolic disturbances, primarily weight gain and losses in triglyceride and high-density lipoprotein (HDL) values, a retrospective study in 128 youngsters showed. However, the changed values usually were within the normal reference values and often were not recognized.
AAP issues recommendations for Williams syndrome
April 1st 2020The American Academy of Pediatrics’ (American Academy of Pediatrics) newly issued recommendations for supervising the health care of children with Williams syndrome are based on a review of the current literature along with the consensus of physicians and psychologists with expertise in managing this condition, which is caused by a deletion of part of chromosome 7.
Fenfluramine may be a new treatment option for Dravet syndrome
March 11th 2020When added to existing antiepileptic treatment, fenfluramine hydrochloride significantly reduced the frequency of convulsive seizures in children and young adults with Dravet syndrome and had a dose-response effect, according to a randomized trial in patients in whom seizures had not been completely controlled by their current treatment regimen.